Leptospirosis in Dogs: Clinical Signs, Diagnostics, and Zoonotic Risk

Introduction

Leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. In dogs, the disease presents a diagnostic challenge due to its variable clinical manifestations, which range from subclinical infection to acute multi-organ failure. The pathogen is maintained in nature through chronic renal carriage in reservoir hosts, and dogs acquire infection through direct or indirect contact with urine from infected animals. This review provides a detailed examination of the etiologic agent, serovar distribution in canine populations, pathophysiological mechanisms, clinical presentation, diagnostic modalities, therapeutic protocols, preventive strategies, and zoonotic implications. The discussion is framed within the context of veterinary clinical practice and public health surveillance.

Etiology and Serovar Epidemiology

The genus Leptospira comprises both saprophytic and pathogenic species. Pathogenic species are classified within the L. interrogans sensu lato complex, which includes L. interrogans sensu stricto, L. kirschneri, L. borgpetersenii, L. noguchii, L. weilii, and others [1, 2]. Classification is based on serovar identity, defined by the antigenic composition of lipopolysaccharide (LPS) and other surface antigens. Over 300 serovars have been described, but only a subset is associated with canine disease [3].

The most frequently implicated serovars in canine leptospirosis vary by geographic region. In North America and Europe, serovars Grippotyphosa, Pomona, Canicola, and Icterohaemorrhagiae are predominant [4, 5]. Serovar Canicola was historically associated with dogs as a maintenance host, but recent epidemiological shifts have shown increased prevalence of serovars associated with wildlife reservoirs, particularly raccoons (Procyon lotor) and opossums (Didelphis virginiana) [6, 7]. Serovar Bratislava, maintained by swine and horses, has also been identified in canine cases [8]. The emergence of serovar Australis in some European canine populations underscores the dynamic nature of leptospiral seroepidemiology [9].

The distribution of serovars is influenced by ecological factors including climate, land use, and wildlife population density. Warmer temperatures and increased rainfall facilitate bacterial survival in the environment, leading to higher transmission rates [10]. Urbanization and encroachment into wildlife habitats increase the probability of contact between dogs and reservoir hosts [11].

Pathophysiology and Host-Pathogen Interactions

Leptospira species are motile, aerobic spirochetes that penetrate the host through mucous membranes or abraded skin. The bacteria possess a double-membrane architecture with an outer membrane containing LPS, transmembrane porins (OmpL1, LipL41), and surface-exposed lipoproteins (LipL32, LipL21) that mediate adhesion to host extracellular matrix components [12, 13]. Motility is conferred by periplasmic flagella, which enable the organism to traverse tissue barriers and disseminate hematogenously [14].

Following penetration, leptospires enter the bloodstream and replicate during a leptospiremic phase that typically lasts 4 to 12 days [15]. The bacteria evade early innate immune responses through complement resistance mediated by factor H binding proteins and by inducing a muted Toll-like receptor 4 (TLR4) response due to structural peculiarities of leptospiral LPS [16, 17]. During this phase, organisms are distributed to multiple organs including the liver, kidneys, lungs, eyes, and central nervous system.

Renal tropism is a hallmark of leptospiral infection. The organisms localize to the proximal renal tubules, where they adhere to tubular epithelial cells via interactions between leptospiral adhesins and host integrins [18]. The resulting tubulointerstitial nephritis is characterized by infiltration of mononuclear cells, tubular necrosis, and fibrosis [19]. Chronic renal carriage can persist for months to years in reservoir hosts and occasionally in dogs, with intermittent shedding of viable organisms in urine [20].

Hepatic involvement manifests as hepatocellular dissociation, canalicular cholestasis, and periportal inflammation. The mechanism of hepatic injury involves direct cytotoxicity from leptospiral hemolysins and sphingomyelinases, as well as immune-mediated damage [21]. Pulmonary hemorrhage, a severe complication, results from damage to pulmonary capillary endothelium and disruption of the alveolar-capillary barrier [22].

Clinical Signs

The clinical presentation of canine leptospirosis is highly variable and depends on the infecting serovar, the infectious dose, the host immune status, and the presence of concurrent disease. Subclinical infections are common, particularly in young dogs with prior exposure to low-virulence strains [23]. Acute disease typically manifests after an incubation period of 5 to 14 days.

Renal and Urogenital Signs

Acute kidney injury (AKI) is the most common clinical manifestation. Affected dogs present with polyuria, polydipsia, vomiting, anorexia, and lethargy. Oliguria or anuria may develop in severe cases. Laboratory findings include azotemia, isosthenuria, and proteinuria [24]. Renal ultrasonography may reveal renomegaly, increased cortical echogenicity, and perirenal fluid accumulation [25].

Hepatic Signs

Icterus is a prominent feature in infections caused by serovar Icterohaemorrhagiae but can occur with other serovars. Hepatomegaly, bilirubinuria, and elevated liver enzyme activities (alanine aminotransferase, alkaline phosphatase) are common. Hyperbilirubinemia results from both hemolysis and hepatocellular dysfunction [26].

Respiratory Signs

Pulmonary involvement ranges from mild tachypnea to severe hemorrhagic pneumonia. Cough, dyspnea, and hemoptysis may be observed. Thoracic radiographs typically show a diffuse interstitial to alveolar pattern, often with a caudodorsal distribution [27]. Pulmonary hemorrhage carries a guarded prognosis.

Other Clinical Signs

Fever, myalgia, stiffness, and reluctance to move are frequently reported. Ocular signs including conjunctivitis, uveitis, and hyphema occur less commonly. Coagulopathies, thrombocytopenia, and disseminated intravascular coagulation (DIC) can complicate the clinical course [28].

Diagnostic Approaches

Definitive diagnosis of canine leptospirosis requires laboratory confirmation due to the non-specific nature of clinical signs. A combination of serological and molecular methods is recommended for optimal sensitivity and specificity.

Microscopic Agglutination Test (MAT)

The MAT remains the reference standard for serological diagnosis. The assay detects agglutinating antibodies (primarily IgM and IgG) against a panel of live leptospiral serovars. A four-fold rise in titer between paired acute and convalescent sera collected 2 to 4 weeks apart is considered diagnostic [29]. A single titer of 1:800 or higher in a dog with compatible clinical signs is strongly suggestive of active infection [30].

The MAT has several limitations. It requires maintenance of live leptospiral cultures, which poses biosafety risks and limits availability to reference laboratories. Cross-reactivity between serovars is common, making serovar identification unreliable. False-negative results can occur in early infection before seroconversion, and false-positive results may arise from prior vaccination [31].

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA-based methods detect IgM and IgG antibodies against leptospiral antigens, typically using whole-cell lysates or recombinant proteins such as LipL32. IgM ELISA is useful for detecting acute infection, while IgG ELISA indicates prior exposure or vaccination [32]. Commercial ELISA kits offer improved throughput and standardization compared to MAT, but sensitivity and specificity vary between manufacturers. The principles of ELISA are analogous to those described for Feline Leukemia Virus p27 antigen detection, though the target analyte differs.

Polymerase Chain Reaction (PCR)

PCR assays targeting conserved leptospiral genes, such as lipL32, secY, or 16S rRNA, provide rapid and sensitive detection of leptospiral DNA in blood, urine, and tissue samples [33]. Real-time PCR (qPCR) allows quantification of bacterial load and can differentiate pathogenic from saprophytic species through melt curve analysis or probe-based genotyping [34].

Blood PCR is most sensitive during the leptospiremic phase (first 4 to 10 days post-infection). Urine PCR is preferred for detecting renal shedding and can remain positive for weeks after clinical resolution [35]. The diagnostic sensitivity of PCR is superior to MAT in the acute phase, but false negatives can occur due to low bacterial numbers or PCR inhibitors in urine.

Culture and Dark-Field Microscopy

Bacterial culture of blood, urine, or tissue is definitive but impractical for routine diagnosis due to the slow growth of Leptospira (up to 16 weeks) and the need for specialized media (e.g., Ellinghausen-McCullough-Johnson-Harris medium) [36]. Dark-field microscopy of urine or blood can detect motile spirochetes, but sensitivity is low and operator expertise is required.

Point-of-Care Testing

Rapid immunochromatographic assays for leptospiral antibody detection are available for in-clinic use. These tests provide qualitative results within 15 minutes but have variable sensitivity compared to MAT and PCR [37]. Their utility is primarily as screening tools in endemic areas or when laboratory access is limited.

Diagnostic Algorithm

The following Mermaid diagram outlines a recommended diagnostic workflow for suspected canine leptospirosis.

flowchart TD
    A[Clinical suspicion: fever, vomiting, azotemia, icterus], > B{Acute phase <10 days?}
    B, >|Yes| C[Collect blood for PCR and MAT acute titer]
    B, >|No| D[Collect urine for PCR and blood for MAT]
    C, > E[PCR positive?]
    E, >|Yes| F[Confirm diagnosis; start treatment]
    E, >|No| G[Collect convalescent serum in 2-4 weeks]
    D, > H[Urine PCR positive?]
    H, >|Yes| I[Confirm renal shedding; treat]
    H, >|No| J[MAT titer >=1:800?]
    J, >|Yes| K[Presumptive diagnosis]
    J, >|No| L[Consider alternative diagnoses]
    G, > M[Four-fold titer rise?]
    M, >|Yes| N[Confirmed leptospirosis]
    M, >|No| O[Leptospirosis unlikely]

Treatment Protocols

Antimicrobial therapy is the cornerstone of treatment for canine leptospirosis. The goals are to eliminate the leptospiremic phase, clear renal carriage, and prevent transmission.

Antimicrobial Agents

Doxycycline is the drug of choice for treating leptospirosis in dogs. It is administered orally or intravenously at a dose of 5 mg/kg every 12 hours or 10 mg/kg every 24 hours for 14 days [38]. Doxycycline achieves high intracellular concentrations and is effective against both the acute phase and renal carriage. Intravenous administration is preferred in dogs with vomiting or gastrointestinal dysfunction.

Penicillin derivatives, including ampicillin (20 mg/kg intravenously every 6 hours) and amoxicillin (20 mg/kg orally every 8 hours), are effective against leptospiremia but do not reliably clear renal carriage [39]. They may be used as initial therapy in dogs with severe AKI where doxycycline is contraindicated, followed by a course of doxycycline after stabilization.

Fluoroquinolones such as enrofloxacin (5 mg/kg every 24 hours) have demonstrated efficacy against Leptospira in vitro and in experimental models, but clinical data in dogs are limited [40]. They are not considered first-line agents.

Supportive Care

Aggressive fluid therapy is essential for managing AKI. Isotonic crystalloids are administered to correct dehydration and maintain urine output. Diuretics (furosemide, mannitol) may be indicated in oliguric patients. Hemodialysis or peritoneal dialysis should be considered for dogs with refractory azotemia or anuria [41].

Hepatic support includes administration of hepatoprotectants (S-adenosylmethionine, silymarin), vitamin K1 for coagulopathy, and nutritional support. Dogs with pulmonary hemorrhage require oxygen supplementation and careful fluid management to avoid volume overload [42].

Prognosis

The prognosis for canine leptospirosis is guarded to good with early and aggressive treatment. Mortality rates range from 10% to 30% in hospitalized dogs [43]. Poor prognostic indicators include severe azotemia, oliguria, pulmonary hemorrhage, and DIC.

Prevention and Vaccination

Vaccination is the most effective strategy for preventing canine leptospirosis. Available vaccines are bacterins containing inactivated whole-cell preparations of multiple serovars. Most commercial vaccines include serovars Canicola, Icterohaemorrhagiae, Grippotyphosa, and Pomona [44]. Quadrivalent vaccines provide broader coverage than bivalent formulations.

The vaccination protocol typically involves an initial series of two doses administered 2 to 4 weeks apart, followed by annual boosters. Puppies should receive the first dose at 8 to 10 weeks of age [45]. Vaccine efficacy is serovar-specific, and breakthrough infections can occur with serovars not included in the vaccine.

Adverse reactions to leptospiral bacterins are more common than with other canine vaccines. Acute anaphylaxis, urticaria, and injection-site reactions have been reported. Premedication with antihistamines may reduce the risk of adverse events in susceptible dogs [46].

Non-pharmaceutical preventive measures include limiting access to standing water, controlling rodent populations, and preventing contact with wildlife. Dogs housed in kennels or with access to rural environments are at increased risk and should be vaccinated.

Zoonotic Risk and Public Health Implications

Leptospirosis is a zoonotic disease of significant public health concern. Dogs serve as potential sources of infection for humans through direct contact with urine or indirectly through contaminated water or soil [47]. The same serovars that infect dogs (e.g., Canicola, Icterohaemorrhagiae, Pomona) are capable of causing disease in humans.

Human leptospirosis ranges from a mild, flu-like illness to severe Weil's disease, characterized by jaundice, renal failure, and pulmonary hemorrhage. The incubation period in humans is 5 to 14 days. Diagnosis in humans relies on similar serological and molecular methods as in dogs [48].

Veterinary personnel, pet owners, and laboratory workers are at increased risk of occupational exposure. Strict hygiene protocols should be followed when handling potentially infected dogs. Gloves should be worn when collecting blood or urine samples, and surfaces contaminated with urine should be disinfected with bleach or other sporicidal agents [49].

Public health authorities recommend reporting confirmed cases of canine leptospirosis to local health departments to facilitate human surveillance and outbreak investigations. The One Health approach, integrating veterinary, environmental, and human health sectors, is essential for effective leptospirosis control [50].

Conclusion

Canine leptospirosis remains a diagnostically challenging and clinically significant disease with substantial zoonotic potential. The shifting serovar epidemiology, driven by wildlife reservoir dynamics and environmental changes, necessitates ongoing surveillance and adaptation of vaccination strategies. Advances in molecular diagnostics, particularly PCR, have improved early detection and differentiation of infecting serovars. Antimicrobial therapy with doxycycline remains the standard of care, and supportive management of AKI and pulmonary complications is critical for favorable outcomes. Prevention through vaccination and biosecurity measures is the cornerstone of population-level control. The zoonotic risk associated with canine leptospirosis underscores the importance of a One Health framework for surveillance, reporting, and public health intervention.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[2] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[3] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[4] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 36 cases (1997-2002). J Am Vet Med Assoc. 2004;225(1):72-77.

[5] Ellis WA. Animal leptospirosis. Curr Top Microbiol Immunol. 2015;387:99-137.

[6] Gautam R, Wu CC, Guptill LF, et al. Detection of Leptospira in urine of dogs and raccoons using polymerase chain reaction. J Wildl Dis. 2010;46(3):855-862.

[7] Richardson DJ, Gauthier JJ. A serosurvey of leptospirosis in Connecticut peridomestic wildlife. Vector Borne Zoonotic Dis. 2003;3(4):187-193.

[8] Ribotta MJ, Higgins R, Gottschalk M, et al. Seroprevalence of Leptospira serovar Bratislava in horses and dogs in Quebec. Can Vet J. 2000;41(7):547-549.

[9] Mayer-Scholl A, Luge E, Draeger A, et al. Distribution of Leptospira serogroups in dogs from Berlin, Germany. Vector Borne Zoonotic Dis. 2014;14(8):584-590.

[10] Lau CL, Smythe LD, Craig SB, et al. Climate change, flooding, urbanisation and leptospirosis: fuelling the fire? Trans R Soc Trop Med Hyg. 2010;104(10):631-638.

[11] Alton GD, Berke O, Reid-Smith R, et al. Increase in seroprevalence of canine leptospirosis and its risk factors, Ontario 1998-2006. Can J Vet Res. 2009;73(3):167-175.

[12] Haake DA, Matsunaga J. Leptospiral immunoglobulin-like proteins and their role in pathogenesis. Curr Top Microbiol Immunol. 2015;387:139-162.

[13] Hauk P, Macedo F, Romero EC, et al. LipL32, the major leptospiral lipoprotein, the C-terminus is the primary immunogenic domain and mediates interaction with collagen IV and plasma fibronectin. Infect Immun. 2008;76(6):2642-2650.

[14] Wunder EA, Figueiredo CP, Benaroudj N, et al. A novel flagellar sheath protein, FcpA, facilitates attachment of Leptospira to host cells. Infect Immun. 2016;84(5):1451-1459.

[15] Faine S, Adler B, Bolin C, et al. Leptospira and Leptospirosis. 2nd ed. Melbourne: MediSci; 1999.

[16] Barbosa AS, Abreu PA, Vasconcellos SA, et al. Immune evasion of Leptospira species by acquisition of human complement regulator C4BP. Infect Immun. 2009;77(3):1137-1143.

[17] Nahori MA, Fournié-Amazouz E, Que-Gewirth NS, et al. Differential TLR recognition of leptospiral lipid A and lipopolysaccharide in murine and human cells. J Immunol. 2005;175(9):6022-6031.

[18] Barnett JK, Barnett D, Bolin CA, et al. Expression and distribution of leptospiral outer membrane components during renal infection of hamsters. Infect Immun. 1999;67(2):853-861.

[19] Sterling CR, Thiermann AB. Urban rats as chronic carriers of leptospirosis: an ultrastructural investigation. Vet Pathol. 1981;18(5):628-637.

[20] Monahan AM, Callanan JJ, Nally JE. Host-pathogen interactions in the kidney during chronic leptospirosis. Vet Pathol. 2009;46(5):792-799.

[21] Seguro AC, Andrade L. Pathophysiology of leptospirosis. Shock. 2013;39(Suppl 1):17-23.

[22] Croda J, Neto AN, Brasil RA, et al. Leptospirosis pulmonary haemorrhage syndrome is associated with linear deposition of immunoglobulin and complement on the alveolar surface. Clin Infect Dis. 2010;50(6):e53-e59.

[23] Greene CE, Sykes JE, Moore GE, et al. Leptospirosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier; 2012:431-447.

[24] Goldstein RE, Lin RC, Langston CE, et al. Influence of infecting serogroup on clinical features of leptospirosis in dogs. J Vet Intern Med. 2006;20(3):489-494.

[25] Forrest LJ, O'Brien RT, Tremelling MS, et al. Sonographic renal findings in 20 dogs with leptospirosis. Vet Radiol Ultrasound. 1998;39(4):337-340.

[26] Rentko VT, Clark N, Ross LA, et al. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[27] Klopfleisch R, Kohn B, Gruber AD. Pulmonary pathology of canine leptospirosis. Vet Pathol. 2010;47(4):727-735.

[28] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome predictors of Leptospira interrogans Australis serogroup infection in dogs: a retrospective study of 20 cases (2001-2004). J Vet Intern Med. 2007;21(1):3-10.

[29] World Organisation for Animal Health (OIE). Leptospirosis. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Paris: OIE; 2018.

[30] Miller MD, Annis KM, Lappin MR, et al. Variability in results of the microscopic agglutination test for leptospirosis in dogs. J Vet Intern Med. 2011;25(3):555-560.

[31] Prescott JF, McEwen B, Taylor J, et al. Resurgence of leptospirosis in dogs in Ontario: recent findings. Can Vet J. 2002;43(12):955-961.

[32] Dey S, Mohan CM, Ramadass P, et al. Recombinant LipL32 antigen-based single serum dilution ELISA for detection of canine leptospirosis. Vet Microbiol. 2007;125(1-2):117-124.

[33] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[34] Ahmed A, Engelberts MF, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical materials. PLoS One. 2009;4(9):e7093.

[35] Harkin KR, Roshto YM, Sullivan JT, et al. Clinical application of a polymerase chain reaction assay for diagnosis of leptospirosis in dogs. J Am Vet Med Assoc. 2003;222(9):1224-1229.

[36] Faine S. Guidelines for the Control of Leptospirosis. Geneva: World Health Organization; 1982.

[37] Lizer J, Velineni S, Weber A, et al. Evaluation of a rapid immunochromatographic test for the detection of antibodies to Leptospira in dogs. J Vet Diagn Invest. 2017;29(4):476-481.

[38] Sykes JE, Hartmann K, Lunn KF, et al. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[39] Alt DP, Bolin CA. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar Pomona infection in hamsters and swine. Am J Vet Res. 1996;57(1):59-62.

[40] Courtin F, Diouf B, Garin B, et al. In vitro activity of fluoroquinolones against Leptospira spp. Antimicrob Agents Chemother. 1994;38(9):2189-2191.

[41] Adin CA, Cowgill LD. Treatment and outcome of dogs with leptospirosis: 36 cases (1990-1998). J Am Vet Med Assoc. 2000;216(3):371-375.

[42] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1277-1282.

[43] Ettinger SJ, Feldman EC. Textbook of Veterinary Internal Medicine. 7th ed. St. Louis: Elsevier; 2010.

[44] Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc. 2005;227(7):1102-1108.

[45] Day MJ, Horzinek MC, Schultz RD, et al. Guidelines for the vaccination of dogs and cats. J Small Anim Pract. 2016;57(1):E1-E45.

[46] Paul MA, Carmichael LE, Childers H, et al. 2006 AAHA canine vaccine guidelines. J Am Anim Hosp Assoc. 2006;42(2):80-89.

[47] Guerra MA. Leptospirosis: public health perspectives. Biologicals. 2013;41(5):295-297.

[48] Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65-97.

[49] National Association of State Public Health Veterinarians. Compendium of veterinary standard precautions for zoonotic disease prevention in veterinary personnel. J Am Vet Med Assoc. 2015;247(11):1252-1277.

[50] One Health Initiative. One Health: a new professional imperative. One Health Newsl. 2008;1(1):1-2.